

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated 7 November 2003

12FEB03 E784133-1 D01298
P01/7700 0.00-0303085.5

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office

 Cardiff Road
 Newport
 South Wales
 NP10 8QQ

11 FEB 2003

1. Your reference

PC25578

2. Patent application number

(The Patent Office will fill in this part)

0303085.5

3. Full name, address and postcode of the or of each applicant (underline all surnames)

 PFIZER LIMITED
 Ramsgate Road,
 Sandwich,
 Kent, CT13 9NJ

Patents ADP number (if you know it)

6892673001

United Kingdom

If the applicant is a corporate body, give the country/state of its incorporation

4. Title of the invention

MODEL

5. Name of your agent (if you have one)

Dr. B. Peter

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

 UK Patent Department
 Ramsgate Road,
 Sandwich, Kent,
 CT13 9NJ
 United Kingdom

1271001

Patents ADP number (if you know it)

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

See note (d)

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form

Description	21
Claim(s)	4
Abstract	0
Drawing(s)	3 +3

John

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination
(*Patents Form 10/77*)

Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature
Boak Peter

Date
11th February 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

Dr. B. Peter

01304.645854

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

Model**Field of the Invention**

5 The invention relates to an animal model for inflammatory bowel disease. More specifically, the invention relates to a murine model for inflammatory bowel disease, which is based on a transgenic mouse lacking mdrla. This model facilitates the characterisation of the pathogenic mechanisms of inflammatory bowel disease and the development of diagnostics, therapies and therapeutic compounds.

10

Background to the Invention

Inflammatory bowel disease (IBD) is a chronic, relapsing and remitting inflammatory condition of unknown origin that afflicts individuals of both sexes throughout life. The 15 disease is clinically characterised by two overlapping conditions, ulcerative colitis (UC) and Crohn's disease (CD). Clinical and laboratory studies in humans with IBD have suggested that genetic and environmental factors play an inter-related role in the pathogenesis of these disorders. More recent immunologic studies suggest that IBD may be due to a dysregulated mucosal immune response to one or more unknown antigens 20 present in the normal bacterial gut flora.

The etiology of inflammatory bowel disease remains unknown despite many years of extensive investigation. Some insight into potential disease mechanisms has however been obtained from various animal models. For example, rodents deficient in genes 25 encoding several cytokines including IL-2 (Sadlack B. et al (1993) Cell 75, 253-261), IL-10 (Kuhn R. et al. (1993) Cell 75, 263-274) and TGF- β (Shull MM. et al. (1992) Nature 359, 693-699) develop spontaneous intestinal inflammation. Selective gene deletion of proteins involved in T cell function, such as G α i2 (Rudolph U et al (1995) Nat Genet 10, 143-150), TCR α (Mombaerts P. et al (1993) Cell, 75, 274-282), and TCR β also results in 30 spontaneous intestinal inflammation. These studies have contributed to the hypothesis that the persistent inflammation seen in IBD may be the result of either enhanced or

aberrant immunological responsiveness to normal constituents of the gut lumen, or an overall autoimmune dysregulation and imbalance.

Intestinal flora may also be an important co-factor in the pathogenesis of intestinal inflammation. For example, in several rodent models spontaneous colitis can be prevented if animals are maintained in a germ-free environment (Dianda L et al (1997) Am J Pathol 1997; 150: 91-97, Taurog JD et al (1994) J Exp Med 180, 2359-2364). Other studies have shown that intestinal inflammation can be successfully treated with oral antibiotics (Panwala CM et al. (1998) J Immunol 161, 5733-5744). In addition, patients with IBD have adverse and enhanced reactivity to their autologous resident flora (MacDonald TT. (1995) Clin Exp Immunol, 102: 445-447). Further support for the hypothesis that intestinal flora may be important in the pathogenesis of intestinal inflammation has been derived from studies using mice with defects in epithelial barrier cell function, induced by deleting genes for trefoil factor (Mashimo H et al (1996) Science 274, 262-265) or N-cadherin (Hermiston ML & Gordon JI. (1995) Science, 270, 1203-1207). These mice also have evidence of inflammation in the gastrointestinal tract. In addition to intestinal flora, it is plausible to hypothesize that food constituents may contribute to the inflammatory response observed in rodents with defective epithelial cell barriers, since they would potentially have access to areas of the gut lumen which they would not have in animals with an intact epithelial barrier.

Intestinal epithelial cells (Croop JM et al. (1989) Mol Cell Biol, 1346-1350; Gottessman MM & Pastan I. (1993) Annu Rev Biochem 62, 385-427), and also some lymphocyte subsets (Bommhardt U et al. (1994) Eur J Immunol, 24, 2974-2981) express multiple drug resistant (mdr) genes. Mdr genes encode P-glycoproteins, which are drug efflux pumps. These pumps are localised in the plasma membranes of many tissues and have a natural role to play in protecting the host from potentially harmful compounds. Three mdr1 genes have been identified in rodents (mdr1a, mdr1b and mdr2) and two in humans (mdr1 and mdr2). In mice, mdr1a P-glycoprotein is also expressed in the blood-brain and blood-testis barrier and mdr1b P-glycoprotein is expressed in adrenal glands, pregnant uterus and ovaries (Bommhardt U et al. (1994) Eur J Immunol, 24, 2974-2981). Both mdr1a and mdr1b P-glycoprotein are expressed in the liver, kidney, spleen and heart.

In 1994 mice with a targeted deletion of the *mdrla* gene were generated. These mice had an increased sensitivity to certain drugs, but did not appear to have any constitutive abnormalities (Schinkel AH et al (1994) *Cell* 77, 491-502). *Mdrla*^{-/-} mice are routinely used in studies to evaluate the involvement of P-glycoprotein in the absorption of compounds, brain penetration of compounds and the hepatobiliary excretion of compounds that are potentially substrates for P-glycoprotein. Interestingly, a recent study reported that approximately 25% of *mdrla*^{-/-} mice spontaneously developed colonic inflammation that is histologically similar to human IBD (Panwala CM et al (1998) *J Immunol* 161, 5733-5744). We have observed similar clinical symptoms and lesions in *mdrla*^{-/-} mice being used for drug metabolism studies, and preliminary data has been reported (Banner KH et al. (2001) *Gastroenterology* 120, A693). Specifically, clinical symptoms included acute body weight loss and soft "sticky" faeces and histopathological analysis revealed a marked diffuse colitis. However, with so few animals developing the symptoms of inflammatory bowel disease, this is not a reliable model that can be used on a routine basis for this disease.

In our work with this transgenic mouse strain for drug metabolism studies, we attempted to reduce the incidence of inflammatory bowel disease-like symptoms in this mouse strain by reducing the bacterial load in the drinking water through addition of chlorine. However, surprisingly, we found that addition of chlorine to the drinking water of the *mdrla*^{-/-} mice led to a significant increase in the incidence of disease, as 100% of the animals which had been drinking chlorinated water developed inflammatory bowel disease-like symptoms which closely resembled the symptoms of inflammatory bowel disease in humans. This was highly unexpected, but it has led to the invention, the first reliable, reproducible animal model for inflammatory bowel disease which histologically closely resembles the human disease.

Now that a robust and reliable animal model is developed for this disease, which shows very similar characteristics to the disease as observed in patients suffering from inflammatory bowel disease, it becomes possible to use the model to study the etiology and progression of the disease and identify new targets for the development of compounds that will be beneficial for the treatment of the disease, be it to eliminate the cause of the

disease or at least halt or slow the progression of the disease or treat the symptoms more effectively than currently available treatments.

5 Aspects of the Invention

The invention is based on the surprising observation that a very high incidence of colitis (with symptoms and histology closely resembling human IBD) is observed in *mdrla*^{-/-} mice when they are supplied with chlorinated drinking water. This observation has led to 10 the development of a robust animal model for IBD, which is useful for testing compounds for their efficacy in treating, curing or preventing IBD, as well as identifying candidate genes which may be involved in the pathogenesis of IBD.

One aspect of the invention is therefore a method of inducing IBD-like symptoms in a 15 mammal, wherein the mammal (i) is a non-human mammal not expressing a functional *mdrla* gene product, and (ii) is supplied with chlorinated drinking water. Another aspect of the invention is a method of inducing IBD-like symptoms in a mammal, wherein the mammal is treated with an inhibitor of the *mdrla* gene product or with a compound that inhibits the expression of the *mdrla* gene product in the gut, and given chlorinated 20 drinking water. The chlorinated drinking water has a chlorine concentration of above 1ppm, preferably above 3ppm, most preferably 5ppm or above. In a preferred aspect, the mammal is a transgenic rodent, preferably a transgenic mouse, not expressing a functional *mdrla* gene. A preferred aspect of the invention is a method as described above wherein more than 50%, preferably more than 70%, more preferably more than 80%, even more 25 preferably more than 90%, and most preferably 100% of the animals show IBD-like symptoms.

The preferred mammal used in the method is a transgenic *mdrla*^{-/-} knockout mouse, even 30 more preferred transgenic mouse strain FVB.129P2-*Pgy3*^{tm1} N7. However, any mammal not expressing the *mdrla* gene product may be used. This may include a mammal with a naturally occurring mutation in both alleles of the *mdrla* gene or its promoter. This may also include a wildtype mammal treated with a compound that inhibits the expression of the *mdrla* gene in the gut of the mammal, e.g. a cAMP dependant protein kinase inhibitor,

a sub-therapeutic dose of mitomycin C or an antisense oligonucleotide specific for the mdr1a orthologue in the mammal of choice. Alternatively the mammal of choice expressing a functional mdr1a gene product may be used in the model provided the mdr1a gene product is effectively inhibited in the gut, e.g. by treatment with a compound that

5 effectively inhibits the mdr1a gene product in the gut of the mammal, e.g. by giving compounds that have been identified as MDR inhibitors or by blocking antibodies specific for mdr1a. Various compounds and mechanisms to inhibit MDR have been reviewed recently (C. Avendano & J.C. Menendez (2002) *Curr. Med. Chem.* 9, 159-193). Alternatively, the mammal of choice may be treated with an antisense oligonucleotide or a

10 ribozyme to inhibit the expression of the mdr1a gene product, prior to use in the IBD model.

Another aspect of the invention is a method of screening a candidate compound for its efficacy in ameliorating the symptoms of IBD, the method comprising the following steps:

- (a) administering the candidate compound in a vehicle to a first non-human mammal not expressing a functional mdr1a gene product (or wherein the mdr1a gene product is effectively inhibited), supplied with chlorinated drinking water;
- (b) administering the vehicle without the candidate compound to a second transgenic non-human mammal not expressing a functional mdr1a gene product (or wherein the mdr1a gene product is effectively inhibited, or wherein the expression of the mdr1a gene product is inhibited), supplied with chlorinated drinking water; and
- (c) comparing the symptoms of IBD in the mammal(s) of (a) and (b), wherein a decrease in symptoms of IBD in the mammal(s) of (a) as compared to the mammal(s) of (b) indicates efficacy of the compound.

A further aspect of the invention is a method of screening a candidate compound for its efficacy in preventing or delaying the development of IBD, the method comprising the following steps:

- (a) administering the candidate compound in a vehicle to a first non-human mammal not expressing a functional mdr1a gene product (or wherein the mdr1a gene product is effectively inhibited, or wherein the expression of the mdr1a gene product is inhibited), before the onset of the disease in said mammal;

(b) administering the vehicle without the candidate compound to a second transgenic non-human mammal not expressing a functional mdr1a gene product (or wherein the mdr1a gene product is effectively inhibited, or wherein the expression of the mdr1a gene product is inhibited), before the onset of the disease in said mammal;

5 (c) giving chlorinated drinking water to the mammal(s) of (a) and (b); and

(d) comparing the onset of any symptoms of IBD in the animals, wherein a delay in or prevention of the onset of symptoms of IBD in the mammal(s) treated with the candidate compound in a vehicle compared to the mammal(s) treated with the vehicle without the candidate compound indicates efficacy of the compound.

10

Yet another aspect of the invention is a method of screening for genes that may be involved in the pathogenesis of IBD and therefore may be novel targets for the development of drugs for the treatment of IBD, comprising the following steps:

15 (a) supplying only chlorinated drinking water to a first non-human mammal not expressing a functional mdr1a gene product (or wherein the mdr1a gene product is effectively inhibited, or wherein the expression of the mdr1a gene product is inhibited);

(b) supplying only unchlorinated drinking water to a second non-human mammal not expressing a functional mdr1a gene product (or wherein the mdr1a gene product is effectively inhibited, or wherein the expression of the mdr1a gene product is inhibited);

20 (c) making RNA preparations from the intestine from both the mammals of (a) and of (b) after the desired time interval; and

(d) comparing the RNA samples, wherein a RNA which shows a difference in these samples indicates a gene that may be implicated in the pathogenesis of IBD.

25

A further aspect of the invention is a method of screening for genes that may be involved in the pathogenesis of IBD comprising the following steps:

30 (a) supplying only chlorinated drinking water to a first non-human mammal not expressing a functional mdr1a gene product (or wherein the mdr1a gene product is effectively inhibited, or wherein the expression of the mdr1a gene product is inhibited);

(b) supplying only chlorinated drinking water to a second non-human mammal expressing a functional mdr1a gene product;

- (c) supplying only unchlorinated drinking water to a third non-human mammal not expressing a functional mdr1a gene product (or wherein the mdr1a gene product is effectively inhibited, or wherein the expression of the mdr1a gene product is inhibited);
- (d) supplying only unchlorinated drinking water to a fourth non-human mammal

5 expressing a functional mdr1a gene product;

- (e) making RNA preparations from the intestine from each of the mammals of (a) to (d) after the desired time interval; and
- (f) comparing the RNA samples,

wherein a RNA which shows a difference between the samples of (a) and (c), but not a

10 similar difference between the samples of (b) and (d), is a gene that may be implicated in the pathogenesis of IBD.

The comparison of the RNA samples mentioned above can be carried out by expression profiling, preferably by differential display PCR or subtractive hybridisation methods,

15 even more preferably by microarray analysis.

Another aspect of the invention is the identification of the human homologue of any candidate gene identified as described above. This can be carried out by using the mammalian candidate gene as a probe to screen a human cDNA library from suitable

20 human gut tissue, followed by sequence analysis of the positive clones; it can also be done by searching databases such as Genbank (Nucl Acids Res. 30, 17-20 (2002)), available for example on the NCBI web site (<http://www.ncbi.nlm.nih.gov/Genbank/GenbankOverview.html>), with the sequence of the mammalian candidate gene. Other useful databases are the EMBL and DDBJ

25 databases which are also part of the International Nucleotide Sequence Database collaboration. These methods and databases are well known to the skilled person. A preferred method for searching the databases would be Blast2 (Altschul, S.F. et al (1997) Nucl. Acids Res. 25, 3389-3402), but other methods well known to the skilled person, such as Fasta, can also be used. The human sequence with the highest similarity to the

30 mammalian sequence used for the search will be the human homologue of the candidate gene in most cases.

A further aspect of the invention is a method of preparing a composition, which comprises

(a) identifying a compound that is capable of ameliorating the symptoms of IBD by the method comprising the following steps:

5 (i) administering the candidate compound in a vehicle to a first non-human mammal not expressing a functional mdrla gene product (or wherein the mdrla gene product is effectively inhibited), supplied with chlorinated drinking water;

10 (ii) administering the vehicle without the candidate compound to a second transgenic non-human mammal not expressing a functional mdrla gene product (or wherein the mdrla gene product is effectively inhibited, or wherein the expression of the mdrla gene product is inhibited), supplied with chlorinated drinking water; and

15 (iii) comparing the symptoms of IBD in the mammal(s) of (i) and (ii), wherein a decrease in symptoms of IBD in the mammal(s) of (i) as compared to the mammal(s) of (ii) indicates efficacy of the compound; and

15 (b) mixing said compound with a carrier.

Yet a further aspect of the invention is a method of preparing a composition which comprises

(a) identifying a compound that is capable of preventing or delaying the development 20 of IBD by the method comprising the following steps:

25 (i) administering the candidate compound in a vehicle to a first non-human mammal not expressing a functional mdrla gene product (or wherein the mdrla gene product is effectively inhibited, or wherein the expression of the mdrla gene product is inhibited), before the onset of the disease in said mammal;

(ii) administering the vehicle without the candidate compound to a second transgenic non-human mammal not expressing a functional mdrla gene product (or wherein the mdrla gene product is effectively inhibited, or wherein the expression of the mdrla gene product is inhibited), before the onset of the disease in said mammal;

30 (iii) giving chlorinated drinking water to the mammal(s) of (i) and (ii); and

(iv) comparing the onset of any symptoms of IBD in the animals,

wherein a delay in or prevention of the onset of symptoms of IBD in the mammal(s) treated with the candidate compound in a vehicle compared to the mammal(s) treated with the vehicle without the candidate compound indicates efficacy of the compound; and

5 (b) mixing said compound with a carrier.

Examples

The examples are included for the purposes of illustration and are not intended to limit the scope of the invention. General methods referred to but not explicitly described herein 5 are reported in the scientific literature and are well known to the skilled person.

List of Figures:

Figure 1: Effect of Dexamethasone on colon to body weight ratio in *mdr1a^{-/-}* mice (mean 10 \pm sem).

Figure 2: Effect of Dexamethasone on caecum to body weight in *mdr1a^{-/-}* mice (mean \pm sem).

Example 1: *Mdr1a^{-/-}* mice as animal model for IBD

15 Materials and Methods

Animals

Forty male *mdr1a^{-/-}* mice (strain FVB.129P2-*Pgy3^{tm1}* N7) and six control male mice (mdr1a^{+/+}) from the same genetic background (FVB; strain FVB/NTac) (6-8 weeks old) were obtained from Taconic Farms (U.S.A). Mice were individually housed in solid 20 bottom cages containing autoclaved Bee Kay bedding from Bantin & Kingman (U.K.) with the addition of Envirodri, a nesting material made from virgin paper, free from deodorising chemicals, to provide enrichment. Mice were fed on RAT & Mouse No 1 maintenance diet (RMI (E) SQC) (Special Diet services, Witham, Essex, U.K.) on arrival at Pfizer. For this study we used bottled water and Klortabs (5ppm) (Arrowmigh 25 Biosciences, U.K.) to eliminate the possibility of water borne spreading of bacterial pathogens and to provide a water supply with constant levels of chlorine. Water was changed twice a week. This study was carried out in accordance with UK legislation and approved by Pfizer's internal ethical review process.

30 Study design and dosing

Prior to commencing the study, all mice (40 *mdr1a^{-/-}* and 6 *mdr1a^{+/+}*) acclimatised for 14 days. From a pilot study (Banner, K.H. et al (2001) Gastroenterology 120, A693)

body weight and soft faeces score were found to be most predictive of GI inflammation and thus in the present study these clinical signs were monitored. A scoring system was devised with different weightings for different clinical signs (Table 1). The intention was that the score should reflect the severity of the colitis.

5

Table 1. Scoring sheet used for each mouse in the pilot study vs. modified scoring sheet used in this study.

Scoring system (pilot study)

Appearance	Score
Piloerection, hunched	2
Behaviour (choose one)	
Subdued, lethargic	2
Prostrated	6
Miscellaneous	
Soiled anus	1
occult blood in faeces	6
soft "sticky" faeces	6
Fresh blood (anus/faeces)	6
Body weight (choose one)	
Absence of gain	1
Body weight loss $\geq 0.5\text{g} / \text{day}$	2
Body weight loss $\geq 20\%$	6
Total:	

Scoring system (present study)

	Score
Miscellaneous	
soft "sticky" faeces	6
Body weight (choose one)	
Absence of gain	1
Body weight loss $\geq 0.5\text{g} / \text{day}$	2
Body weight loss $\geq 20\%$	6
Total:	

Judgement:

0 - 3 normal

4 - 10 clinical disease

CONSIDER

EUTHANASIA

> 11 clinical disease
close observation (3 /day)

During the acclimatisation period, clinical signs of colitis developed in 8 mice,
 10 which were euthanased (5 *mdr1a*^{-/-} mice) or died (3 *mdr1a*^{-/-} mice). Clinical scores were then used to randomise the remaining *mdr1a*^{-/-} mice into 4 groups treated subcutaneously with vehicle (water) (n=8) or dexamethasone (0.05mg/kg, n=9; 0.3mg/kg, n=8 or 2mg/kg, n=8) daily for 7 days. The 6 *mdr1a*^{+/+} mice received vehicle (water). During the study period one mouse from the group treated with 0.3mg/kg dexamethasone was found dead
 15 and two were euthanised (one from the vehicle treated group and one from the group treated with 0.05mg/kg dexamethasone).

At the end of the study all mice were euthanased. The colon and caecum from each mouse was removed and weighed. Each colon was then divided longitudinally so that one section could be processed for histological analysis and the other for cytokine measurement (see below).

5

Cytokine and protein measurement

Each individual colon sample was homogenised three times for 30 seconds at 4°C in 3ml of ice-cold Krebs' solution (Sigma Chemical Co. U.K.). Samples were centrifuged for 15min at 35,000g (4°C) and supernatants were removed. IL-8 and IFN- γ levels were 10 then measured by ELISA kits (R&D systems, U.K.). The detection limits of these kits were 31.2-2000pg/ml. Protein levels was assayed in supernatants using the method described by Bradford (Bradford, M. (1976) *Analyst. Biochem.* 72, 248-254), utilising Bradford Reagent (Sigma).

15 Histological Analysis

The animals were necropsied. The colon/rectum and caecum were weighed and colon/rectum, caecum, ileum, jejunum, duodenum, stomach, mesenteric nodes, thymus, kidney, spleen were sampled and fixed in 10% buffered formalin solution. The colon/rectum and ileum were prepared in a "Swiss roll" technique (Moolenbeek, C. & 20 Ruitenberg E.J. (1981) *Lab Anim.* 15(1):57-9) to evaluate their whole longitudinal section on one slide. Tissues were processed routinely in an automatic tissue processor, embedded in paraffin, sectioned at 4-6 μ m, stained with hematoxylin and eosin (HE), and examined histologically. The colitis was graded from 0 (no significant findings) to 4 (severe proliferative and ulcerative inflammation) according to the extent of the findings 25 and severity of mucosal changes (Table 2) by a blinded observer. In addition, the mucosal height of the whole colon/rectum were assessed about every 100 μ m with a standard interactive microcomputer-assisted image analysis system.

Score	
0	No significant findings
1	minimal multifocal mucosal changes involving the apex of the mucosal folds of the proximal colon
2	mild multifocal mucosal changes mainly localised within the mucosal folds of the proximal colon. Minimal involvement of the remaining areas
3	Marked mucosal changes involving diffusely the whole middle and distal colon and rectum. Mild multifocal changes in the proximal colon.
4	severe mucosal changes involving diffusely the whole middle and distal colon and rectum. Mild to moderate diffuse changes in the proximal colon.

Table 2. Histological scoring system for colitis

5 Colitis appeared to begin within the proximal region of the colon as this was the main region affected in scores 1 and 2. When the severity of changes increased (scores 3 and 4), lesions were more prominent in the middle and distal regions of the colon and in the rectum. The colitis was characterized histologically by variable infiltration of inflammatory cells within the lamina propria, mainly macrophages, lymphocytes and 10 polynuclear neutrophils and mucosal thickening. Increase in crypt lengths, increased basophilia and number of mitoses of lining enterocytes, goblet cell loss and interstitial oedema were observed. While only a few erosions were seen in score 2, obliteration of normal architecture, superficial to transmural ulcerations and crypt abscesses were seen from score 3.

15

Analysis of Pathogens

A number of pathogens such as *Helicobacter hepaticus*, *Helicobacter bilis*, *Helicobacter rodentium* have been associated with the development of gastrointestinal inflammation in rodents. Three separate techniques were therefore used to confirm the 20 presence or absence of all known murine pathogens in faecal and colon samples. Faecal

samples were analysed using PCR, by two independent collaborators. Colon samples were analysed by electron microscopy and histology using Warthin Starry and Fite Faraco stains. Serological and bacteriological studies were also carried out according to FELASA recommendations (Report of FELASA working group (1996) Laboratory Animals 30, 193-208 & (1994) Laboratory Animals 28; 1-12).

Statistical Analysis

Data were analysed for the 29 $mdrla^{-/-}$ and 6 $mdrla^{+/+}$ mice, which completed the study. Differences between vehicle treated $mdrla^{-/-}$ and $mdrla^{+/+}$ mice were analysed 10 using a two sample t-test (assuming equal variance for IFN- γ , growth rate in the acclimatisation period and final weight, and unequal variance for IL-8, colon weight, caecum weight, colon to body weight ratio, caecum to body weight ratio and growth rate during the study period). The effects of dexamethasone treatment were analysed using 15 analysis of variance (ANOVA) allowing for culling group. Where treatment effects were found to be significant, then 95% confidence intervals were calculated.

Colitis severity score is an ordered categorical measure graded on a scale of 0-4. This type of data is generally analysed using a proportional odds model, however due to the small sample size this was not appropriate and ANOVA was used. This makes the assumption of having normally distributed data, which although we had categorical data, 20 seemed to hold approximately true. All analysis was carried out using Genstat 5 Release 4.2 for Windows.

Results

Clinical signs of colitis

25 Growth rate

There was no statistically significant difference in growth rate during the acclimatisation period between $mdrla^{-/-}$ and $mdrla^{+/+}$ mice (0.265g/day vs. 0.294g/day). However during the study period, there was a statistically significant difference between vehicle treated $mdrla^{-/-}$ and $mdrla^{+/+}$ mice. $mdrla^{+/+}$ mice continued to gain weight 30 whereas $mdrla^{-/-}$ mice lost weight (Table 3). In addition, at the end of the study, vehicle treated $mdrla^{-/-}$ mice were significantly lighter than $mdrla^{+/+}$ mice (Table 3). Dexamethasone treatment had no significant effect on either growth rate or final body weight at any of the doses used (Table 3).

	Treatment (dosed s.c.)	Growth rate (g/day) (Mean \pm s.e.m.)	Body weight (g) (Mean \pm s.e.m.)	Clinical score (Mean \pm s.e.m.)
mdr1a ^{+/+}	vehicle	0.149 \pm 0.039	27.1 \pm 0.55	0
mdr1a ^{-/-}	vehicle	-0.44 \pm 0.099*	22.8 \pm 0.77*	50 \pm 8.9
mdr1a ^{-/-}	0.05 mg/kg dexamethasone	-0.427 \pm 0.099*	22.2 \pm 0.77*	56 \pm 8.9
mdr1a ^{-/-}	0.3 mg/kg dexamethasone	-0.260 \pm 0.099*	22.6 \pm 0.77*	37 \pm 8.9
mdr1a ^{-/-}	2 mg/kg dexamethasone	-0.271 \pm 0.093	22.7 \pm 0.72*	32 \pm 8.3

Table 3: Growth Rate and body weight over study period (allowing for culling group).

*: Two sample t test: *P<0.05 vs mdr1a^{+/+}

5

Clinical scores

Dexamethasone had no effect on overall clinical scores of colitis (see Table 3 above).

Macroscopic evidence of colitis10 Colon and caecum weights

A significant increase in colon (691 ± 69 vs. 325 ± 26 mg) and caecum (211 ± 12 vs. 165 ± 6 mg) weight was observed in the vehicle treated mdr1a^{-/-} mice vs. mdr1a^{+/+} mice. Ratios of colon to body weight (Figure 1, showing mean \pm sem. Open bar represents mdr1a^{+/+} mice and filled bars represent mdr1a^{-/-} mice. * Statistically significant difference

15 compared to 0mg/kg mdr1a^{-/-} group ($p<0.05$.) and caecum to body weight (Figure 2; showing mean \pm sem. Open bar represents mdr1a^{+/+} mice and filled bars represent mdr1a^{-/-} mice. * Statistically significant difference compared to 0mg/kg mdr1a^{-/-} group ($p<0.05$). ** Statistically significant difference compared to 0mg/kg mdr1a^{-/-} group ($p<0.01$). were also significantly higher in vehicle treated mdr1a^{-/-} mice vs. mdr1a^{+/+} mice, 3.0 ± 0.31 vs.

20 1.2 ± 0.08 and 0.9 ± 0.05 vs. 0.6 ± 0.02 respectively. Dexamethasone (2mg/kg s.c. daily for 7 days) reduced absolute colon weight (456 ± 48 vs. 691 ± 52 mg; $P<0.01$) and colon

to body weight ratio (2.1 ± 0.26 vs. 3.0 ± 0.28 , $P=0.017$) vs. vehicle treated $mdr1a^{-/-}$ mice, whilst lower doses of dexamethasone had no significant effect (Figure 2). All doses of dexamethasone tested reduced absolute caecum weights ($p<0.01$) as well as caecum to body weight ratios ($p<0.015$) compared to vehicle treated $mdr1a^{-/-}$ mice.

5

3. Microscopic evidence of colitis

Cytokine levels

IL-8 ($p=0.028$) and IFN- γ ($p<0.01$) levels were significantly higher in homogenised colons from vehicle treated $mdr1a^{-/-}$ mice vs. $mdr1a^{+/+}$ mice.

10 Dexamethasone treatment however, had no effect on levels of either cytokine at any of the doses used (Table 4).

	Treatment	Mean \pm s.e.m (pg/mg protein)	
		IL-8	IFN- γ
$mdr1a^{+/+}$	vehicle	87 ± 10.6	26 ± 12.3
$mdr1a^{-/-}$	vehicle	208 ± 65.7	142 ± 32.6
$mdr1a^{-/-}$	0.05mg/kg dexamethasone	317 ± 65.7	177 ± 32.6
$mdr1a^{-/-}$	0.3mg/kg dexamethasone	264 ± 65.7	169 ± 32.6
$mdr1a^{-/-}$	2mg/kg dexamethasone	220 ± 61.5	100 ± 30.5

Table 4: Levels of IL-8 and IFN- γ in homogenised colon samples from $mdr1a^{+/+}$ and $mdr1a^{-/-}$ mice (allowing for culling group)

15

Histological grading

Colons from $mdr1a^{+/+}$ mice appeared normal. In contrast, colons from $mdr1a^{-/-}$ mice were characterised by lesions similar to those observed in human IBD. Specifically, a severe spontaneous inflammation of the colon with a significant thickening of the mucosa was

20 seen together with occasional crypt abscesses, increases in crypt length and ulcerations which extended through the mucosa to the muscle (which muscle layer). In addition, a dysregulated epithelial cell growth together with an inflammatory cell infiltrate into the lamina propria was observed. There was a decreasing trend in colitis severity score with increasing dose of Dexamethasone. There was not a statistically significant overall
25 difference between the treatment means ($p > 0.10$) but there was some evidence that the

highest dose of Dexamethasone (2 mg/kg) significantly decreased the colitis severity score compared with that in the vehicle group. (Table 5).

	Treatment (dosed s.c.)	Mean \pm s.e.m.	Difference from vehicle	p-value
mdrla ^{+/+}	vehicle	0		
mdrla ^{-/-}	vehicle	3.7 \pm 0.42		
mdrla ^{-/-}	0.05 mg/kg dexamethasone	4.0 \pm 0.42	0.3	> 0.05
mdrla ^{-/-}	0.3 mg/kg dexamethasone	3.1 \pm 0.42	-0.6	> 0.05
mdrla ^{-/-}	2 mg/kg dexamethasone	2.4 \pm 0.39	-1.3	< 0.05

5 Table 5: Effect of dexamethasone (0-2mg/kg) on colitis severity scores graded histologically.

Morphometry assessment

10 The morphometry assessment of the height of the mucosa was in agreement with the histological evaluation. When compared to Score 0, changes in mucosal height were close for scores 1 and 2 (minimal to mild, seen mainly in the proximal region of the colon) and for scores 3 and 4 (marked to severe, prominent in the middle and distal regions of the colon and in the rectum (Figure 3). Also of note is the decrease in the 15 length of the colon/rectum as the severity score of the colitis increases, a classical finding of colitis

Pathology

20 The absence of Helicobacters (H. Bilis, Hepaticus and spp) was confirmed by PCR, electron microscopy and histological staining. Absence of other known pathogens including citrobacter rodentium (bacteria associated with colonic hyperplasia) was confirmed by bacteriological and serological analysis. In summary, mice were free of viruses, bacteria and parasites known to be pathogenic as specified in FELASA recommendations (Report of FELASA working group (1996) Laboratory Animals 30, 25 193-208 & (1994) Laboratory Animals 28; 1-12).

Example 2: Controlled study

16 $mdrla^{-/-}$ mice and 16 $mdrla^{+/+}$ mice of otherwise identical genetic background are acclimatised with unchlorinated drinking water. The animals are then divided into groups 5 as shown in the Table below (Table 6):

Group	Mouse	Drinking water
1	$Mdr1a^{+/+}$	unchlorinated
2	$Mdr1a^{+/+}$	5ppm chlorinated water
3	$Mdr1a^{-/-}$	unchlorinated
4	$Mdr1a^{-/-}$	5ppm chlorinated water

Table 6: study design

The mice are then monitored for soft faeces and absence of body weight gain for up to 5 weeks.

10

Severe IBD-like symptoms are observed only in group 4.

Example 3: Compounds for treatment of IBD

15

40 $mdrla^{-/-}$ mice are acclimatised, and then given 5ppm chlorinated drinking water for 2 days. They are then divided into 4 groups:

10 animals: given vehicle only

10 animals: given test compound at 0.05 mg/kg

20 10 animals: given test compound at 0.5 mg/kg

10 animals: given test compound at 5 mg/kg

Symptoms of IBD are monitored for 3-4 weeks, using one of the methods described in Example 1. A test compound is considered promising for the treatment of IBD if a significant, dose-related improvement is observed in the animals treated with the test

25 compound as compared with the animals which are given vehicle only.

Example 4: Prevention of IBD

40 *mdrla*^{-/-} mice are acclimatised for 2 days, during which they are given unchlorinated drinking water. They are then divided into 4 groups:

- 5 10 animals are given vehicle only
- 10 animals are given 0.05 mg/kg of test compound
- 10 animals are given 0.5 mg/kg of test compound
- 10 animals are given 5 mg/kg of test compound
- 10 The following day, the animals are supplied with chlorinated (5ppm) drinking water. The animals are then monitored for the onset of IBD-like symptoms.

A test compound is considered promising for the prevention of IBD if a significant, dose-related decrease or delay in the onset of symptoms is observed in the animals treated with 15 the test compound as compared with the animals which are given vehicle only.

Example 5: Comparison of changes in gene expression in colons from *mdrla*^{-/-} vs wild type (FVB) mice, and the effect of dexamethasone on these changes

20

The aims of the study were to compare changes in gene expression in colons from FVB wildtype vs. *mdrla*^{-/-} mice and to examine the effect of dexamethasone on these changes.

Male FVB wildtype and *mdrla*^{-/-} mice (9-10 weeks old) were dosed with dexamethasone 25 (2mg/kg i.p.) or vehicle (water) daily for 7 days. Mice were culled and colons removed for histological assessment. RNA was purified from a single donor from each group using a modified Trizol and RNeasy protocol, yielding greater than 50 ug RNA/sample, with a A260/A280 purity greater than 1.9.

30 Performed according to Affymetrix manual: For each sample 10 µg of total RNA was reverse transcribed into double-stranded (ds) cDNA. Half of the ds cDNA was In Vitro Transcribed (IVT) in the presence of biotinylated nucleotides. 25 µg of the IVT product

was fragmented and about 15 µg was used in hybridisation cocktail to hybridise to Test 2 chip and then to U74A chips (see Affymetrix manual a.f.1,7307-1).

RNA quality and hybridisation signal were good in all samples. Mouse U74A data was
5 normalised to 300. Total number of probe sets (~genes) 12,639

Analysis of the data showed that *mdr1a*^{-/-} mice showed clear evidence of increased
inflammation as indicated by, for example, upregulation of inflammatory markers such as
complement components, MHC molecules, leukocyte markers (indicating infiltration of
10 leukocytes into the tissue), cytokines, chemokines, integrins, cyclooxygenase-2 and TNF
family molecules and ligand, as well as showing evidence of tissue destruction as
indicated by, for example, upregulation of metalloproteinase expression.

Candidate drug targets are, for example, genes that are upregulated in *mdr1a*^{-/-} mice and
15 that are brought down to near normal levels by the dexamethasone treatment.

**Example 6: Time course of changes in gene expression in *mdr1a*^{-/-} mice after switch
to chlorinated drinking water as compared to wildtype mice.**

20

To identify genes involved in the pathogenesis of IBD, changes in gene expression in the
colon in *mdr1a*^{-/-} mice as compared to the FVB wildtype mice are studied over time after
switching the mice to chlorinated drinking water.

25 Male mice (9-10 weeks old) (same number of wildtype and *mdr1a*^{-/-}) are acclimatised,
receiving unchlorinated drinking water, for 2 days. The water is then changed to
chlorinated drinking water (5ppm), and mice from each group in parallel are culled and
colons removed for histological assessment and RNA isolation just before and at various
time points after they have started drinking the chlorinated water. Suitable time points
30 would be 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 48 hours, 72 hours.

The expression profiling is carried out as described in the previous Example.

Genes that may be involved in the pathogenesis of IBD are those that change in expression in *mdr1a*^{-/-} mice but not (or not to the same extent) in wildtype mice. Especially interesting are genes that change early after switching the water supply, as these may be genes involved in the onset of the disease, and inhibiting those may prevent 5 the onset of the disease.

Claims:

1. A method of inducing IBD-like symptoms in a mammal, wherein the mammal (i) is a non-human mammal not expressing a functional mdr1a gene product, and (ii) is supplied with chlorinated drinking water.
5
2. A method of inducing IBD-like symptoms in a mammal, wherein the mammal is treated with an inhibitor of the mdr1a gene product and given chlorinated drinking water.
10
3. The method of claim 1 or claim 2, wherein the concentration of chlorine in the drinking water is above 1ppm.
4. The method of any one of claims 1 to 3, wherein the concentration of chlorine in the drinking water is above 3 ppm.
15
5. The method of any one of claims 1 to 4, wherein the concentration of chlorine in the drinking water is 5ppm or above.
20
6. The method of claim 1, claim 3, claim 4 or claim 5, wherein the mammal is a transgenic mdr1a^{-/-} knockout mouse.
7. The method of any one of claims 1 to 6, wherein IBD-like symptoms occur in close to 100% of the mammals.
25
8. A method of screening a candidate compound for its efficacy in ameliorating the symptoms of IBD, the method comprising the following steps:
 - (a) administering the candidate compound in a vehicle to a first non-human mammal not expressing a functional mdr1a gene product (or wherein the mdr1a gene product is effectively inhibited, or wherein the expression of the mdr1a gene product is effectively inhibited), supplied with chlorinated drinking water;
30
 - (b) administering the vehicle without the candidate compound to a second transgenic non-human mammal not expressing a functional mdr1a gene product (or wherein

the mdr1a gene product is effectively inhibited, or wherein the expression of the mdr1a gene product is effectively inhibited), supplied with chlorinated drinking water; and

(c) comparing the symptoms of IBD in the mammal(s) of (a) and (b),
5 wherein a decrease in symptoms of IBD in the mammal(s) of (a) as compared to the mammal(s) of (b) indicates efficacy of the compound.

9. A method of screening a candidate compound for its efficacy in preventing or delaying the development of IBD, the method comprising the following steps:

10 (a) administering the candidate compound in a vehicle to a first non-human mammal not expressing a functional mdr1a gene product (or wherein the mdr1a gene product is effectively inhibited, or wherein the expression of the mdr1a gene product is effectively inhibited), before the onset of the disease in said mammal;

(b) administering the vehicle without the candidate compound to a second transgenic
15 non-human mammal not expressing a functional mdr1a gene product (or wherein the mdr1a gene product is effectively inhibited, or wherein the expression of the mdr1a gene product is effectively inhibited), before the onset of the disease in said mammal;

(c) giving chlorinated drinking water to the mammal(s) of (a) and (b); and

20 (d) comparing the onset of any symptoms of IBD in the animals, wherein a delay in or prevention of the onset of symptoms of IBD in the mammal(s) treated with the candidate compound in a vehicle compared to the mammal(s) treated with the vehicle without the candidate compound indicates efficacy of the compound.

25 10. A method of screening for genes that may be involved in the pathogenesis of IBD comprising the following steps:

(a) supplying only chlorinated drinking water to a first non-human mammal not expressing a functional mdr1a gene product (or wherein the mdr1a gene product is effectively inhibited, or wherein the expression of the mdr1a gene product is effectively inhibited);

30 (b) supplying only unchlorinated drinking water to a second non-human mammal not expressing a functional mdr1a gene product (or wherein the mdr1a gene product

is effectively inhibited, or wherein the expression of the *mdrla* gene product is effectively inhibited);

(c) making RNA preparations from the intestine from both the mammals of (a) and of (b) after the desired time interval; and

5 (d) comparing the RNA samples,
wherein a RNA which shows a difference in these samples indicates a gene that may be implicated in the pathogenesis of IBD.

11. A method of screening for genes that may be involved in the pathogenesis of IBD
10 comprising the following steps:

(a) supplying only chlorinated drinking water to a first non-human mammal not expressing a functional *mdrla* gene product (or wherein the *mdrla* gene product is effectively inhibited, or wherein the expression of the *mdrla* gene product is effectively inhibited);

15 (b) supplying only chlorinated drinking water to a second non-human mammal expressing a functional *mdrla* gene product;

(c) supplying only unchlorinated drinking water to a third non-human mammal not expressing a functional *mdrla* gene product (or wherein the *mdrla* gene product is effectively inhibited, or wherein the expression of the *mdrla* gene product is effectively inhibited);

20 (d) supplying only unchlorinated drinking water to a fourth non-human mammal expressing a functional *mdrla* gene product;

(e) making RNA preparations from the intestine from each of the mammals of (a) to
(d) after the desired time interval; and

25 (f) comparing the RNA samples,
wherein a RNA which shows a difference between the samples of (a) and (c), but not a similar difference between the samples of (b) and (d), is a gene that may be implicated in the pathogenesis of IBD.

30 12. The method of claim 10 or claim 11, wherein the RNA samples are compared by expression profiling.

13. The method of claim 12, wherein the expression profiling is performed by microarray analysis.
14. The method of any one of claims 10 to 13, further comprising the step of identifying the human homologue of the identified gene.
15. A method of preparing a composition which comprises
 - (a) identifying a compound that is capable of ameliorating the symptoms of IBD by the method of claim 8; and
 - (b) mixing said compound with a carrier.
16. A method of preparing a composition which comprises
 - (a) identifying a compound that is capable of preventing or delaying the development of IBD by the method of claim 9; and
 - (b) mixing said compound with a carrier.




Figure 1: Effect of Dexamethasone on the colon to body weight ratio in *mdrla*^{-/-} mice

Figure 2: Effect of Dexamethasone on the caecum to body weight ratio in $mdr1a^{-/-}$ mice.



15

Figure 3: Height of the colon/rectum mucosa throughout the whole colon/rectum.



5

10